Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06420492 · ClinicalTrials.gov registry record · Phase 2

Study of Novel Therapeutics for Acute Remedy of Colitis

A Phase 2 study of Ulcerative Colitis and Ulcerative Colitis Chronic Moderate, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
2
Study locations

NCT06420492 is a Phase 2 study of Ulcerative Colitis and Ulcerative Colitis Chronic Moderate that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06420492, a Phase 2 study of Ulcerative Colitis and Ulcerative Colitis Chronic Moderate, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with acute ulcerative colitis. Patients who qualify are adults who have not responded to treatments for their severe ulcerative colitis. Participation in this study will take 12 weeks long and the study is structured as an open-label pilot study in which participants will take the study drug for 4 weeks in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study will require participants to attend 8 study visits, all of which will be conducted at a study site. Participation will involve taking an oral medication twice daily, tracking the medication in a log, and getting blood drawn and giving a stool and urine sample for a few lab tests throughout the study. Participants may also undergo a flexible sigmoidoscopy at the beginning and end of the study.

Conditions Studied

Ulcerative Colitis Ulcerative Colitis Chronic Moderate Ulcerative Colitis Chronic Severe

Interventions

  • DRUG BRS201

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Chestnut Hill
  • Brigham and Women's Hospital - Chestnut Hill

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-09-30
Est. Completion 2027-06-01
Phase Phase 2

Sponsor

Brigham and Women's Hospital

937 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06420492

The ClinicalTrials.gov registry entry for NCT06420492 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which BRS201 is the first listed.

NCT06420492 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06420492 about?

NCT06420492 is a clinical study titled "Study of Novel Therapeutics for Acute Remedy of Colitis". This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with acute ulcerative colitis. Patients who qualify are adults who have not responded to treatments for their severe ulcerative colitis. Participation in this study will take 12 weeks long...

What is the current status of trial NCT06420492?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-09-30. Estimated completion is 2027-06-01.

What conditions does trial NCT06420492 study?

This clinical trial studies the following conditions: Ulcerative Colitis, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe.

What interventions are being tested in trial NCT06420492?

The interventions under investigation include: BRS201 (DRUG).

Who is sponsoring clinical trial NCT06420492?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06420492 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ulcerative Colitis

All registered trials for this condition

Ulcerative Colitis Chronic Moderate

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.